drug_type
RELEVANT_DRUG
intervention_type
CAR T-cell therapy
drug_description
Autologous CD19-directed CAR T-cell therapy (gene-modified cellular immunotherapy). Engineered T cells express a CAR with CD3ΞΆ signaling and costimulatory domains to target CD19 on B cells, leading to T-cell activation/expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing; expected on-target B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
relmacabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-directed chimeric antigen receptor (with CD3zeta signaling and costimulatory domains). Upon binding CD19 on B cells, the CAR activates T-cell signaling, leading to T-cell activation and expansion, cytokine release, and perforin/granzyme-mediated killing of malignant B cells, with expected on-target B-cell aplasia.
drug_name
Relmacabtagene autoleucel (relma-cel)
nct_id_drug_ref
NCT06365671